These 2 Elements in Novavax's Earnings Report Could Mean Billions for the Biotech

Novavax (NASDAQ:NVAX) reported a widening loss in the most recent quarter. And, as a clinical-stage biotech, the company doesn't generate product revenue. But I'm not surprised or worried about those facts. I'm more focused on two elements in the earnings report that could mean billions of dollars in revenue for Novavax -- as early as this year.